Effect of serum cystatin C in early diabetic nephropathy in type 2 Iraqi diabetic patients

Abstract

Objective This study aimed to find the effect of serum Cystatin C in early diabetic nephropathy. Method This study was conducted in Al Kindy Teaching Hospital during the period from December, 2015 to June, 2016. The study included 90 subjects (30 males and 30 females) with diabetic type 2 and 30 healthy control. Age is between 30 and 70 years. Patients were with no history of liver disease, thyroid or other endocrine diseases through clinical interviewing. They were divided in to three groups. 30 healthy controls, 30 patients with type 2 diabetes mellitus with no albuminuria (albumin excretion in urine <30 µg/ml) and 30 patients with type 2 diabetes mellitus with micro albuminuria (albumin excretion in urine >30 µg/ml). Results There were no significant differences in age, body mass index (BMI) among the studied groups (p > 0.05). Serum Cystatin C levels showed significant difference (p < 0.001) among studied groups, it was significantly higher in micro albuminuria than the other two groups. There was highly significant positive correlation between Cystatin C and serum creatinine (r = 0.697, p < 0.001), and a significant negative correlation between Cystatin C and GFR (r = − 0.455, p = 0.011) and showed significant positive correlation between Cystatin C and urine albumin (r = 0.526, p = 0.003) in type 2 diabetic patients with micro albuminuria. Conclusion Cystatin C is negatively correlated with the amount of GFR, so that Cystatin C considered reliable and sensitive marker for identifying changes in GFR. In type 2 diabetes mellitus with micro albuminuria serum Cystatin C level considered predict marker for renal failure.

Renoprotective Potency of Sitagliptin versus Pioglitazone in Type 2 Diabetic Patients: Impact on LncMIAT

“…For glomerular filtration markers, cystatin-C and creatinine clearance, the current results found that cystatin-C significantly increased in the P group and SL group as compared with both SM and control groups, which illustrates the role of long-term sitagliptin treatment in preventing GFR decline in the SM group. The current results are in accordance with those of Al-Saedy et al, who showed the reverse relationship between cystatin-C and GFR and recommended the use of cystatin-C as an accurate marker of high sensitivity to detect changes in GFR. Moreover, serum cystatin-C level can be utilized as a predictable marker for kidney damage in T2DM with microalbuminuria.…”